# Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?

> PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9156052-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9156052-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9156052-leuprolide-v1.json
- Content SHA-256: `8cdc7cf68fe9b20f74d145760eb52d8b0257b6fbe994080f915929f14a327be6`

## Claims and source pins

### Headline

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

### Summary

PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

### Paragraph 1

PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

## Sources

<a id="source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"></a>
- **Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? · retained source version 1:2013-11-21:current:b51eb4621813afe7992641f0c673678bed5182ff92e0ff74767c41f0abb1cec9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9156052/) (`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9156052-leuprolide-v1.json SHA-256: 8cdc7cf68fe9b20f74d145760eb52d8b0257b6fbe994080f915929f14a327be6.